Jane Bleeg
9 Years at AB|21 Years of Experience
Jane Bleeg is a Senior Vice President and Portfolio Manager for the Global Healthcare team. Prior to this, she was a portfolio manager for European Value Equities—a role she assumed in 2022. Before that, Bleeg was a senior research analyst responsible for European healthcare and US large-cap pharmaceutical companies for the Value Equities Group. Before joining the firm in 2016, she was an engagement manager in the life sciences practice of L.E.K. Consulting, an analyst for Great Point Partners, a healthcare hedge fund, and an investment banking analyst in the healthcare investment banking group at Piper Jaffray & Co. Bleeg holds a BBA (magna cum laude) in finance from the University of Notre Dame and an MBA (with distinction) from Saïd Business School at the University of Oxford. Location: London
Published Work
AI is a potential boon to healthcare companies, but business fundamentals—not the latest science—are the true test of staying power.
Investors in European bank shares have been rattled by recent turmoil in the sector. But many banks are in much better shape than widely perceived.
Healthcare stocks have underperformed this year amid growing fears about pressure on US drug prices. But in pockets of the European healthcare industry where these fears are overdone, we think selective investors can find attractive opportunities.